Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Jennifer Gansert"'
Autor:
Josep Tabernero, Dominic Smethurst, Elwyn Loh, Jennifer Gansert, Lisa Chen, Kelly S. Oliner, Ian McCaffery, Rui Tang, Hongjie Deng, Hans Prenen, Elena Elez, Joe Stephenson, Irina Davidenko, Edith Mitchell, Niall C. Tebbutt, Anna Świeboda-Sadlej, Elzbieta Nowara, Cathy Eng, Eric Van Cutsem
PDF file - 22K, Supplemental Fig. S3. Effect of cytoplasmic MET immunohistochemistry (IHC) staining on objective response rate in patients treated with panitumumab (pmab) plus rilotumumab (AMG 102) versus pmab plus placebo.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::579be5694b8dcf083a41430c5de24fa7
https://doi.org/10.1158/1078-0432.22447464.v1
https://doi.org/10.1158/1078-0432.22447464.v1
Autor:
Josep Tabernero, Dominic Smethurst, Elwyn Loh, Jennifer Gansert, Lisa Chen, Kelly S. Oliner, Ian McCaffery, Rui Tang, Hongjie Deng, Hans Prenen, Elena Elez, Joe Stephenson, Irina Davidenko, Edith Mitchell, Niall C. Tebbutt, Anna Świeboda-Sadlej, Elzbieta Nowara, Cathy Eng, Eric Van Cutsem
PDF file - 37K, Supplemental Fig. S4. The effect of baseline IGF and IGF-related protein expression on overall survival.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fa54745b1bd504f4572d41f9069c652
https://doi.org/10.1158/1078-0432.22447461.v1
https://doi.org/10.1158/1078-0432.22447461.v1
Autor:
Josep Tabernero, Dominic Smethurst, Elwyn Loh, Jennifer Gansert, Lisa Chen, Kelly S. Oliner, Ian McCaffery, Rui Tang, Hongjie Deng, Hans Prenen, Elena Elez, Joe Stephenson, Irina Davidenko, Edith Mitchell, Niall C. Tebbutt, Anna Świeboda-Sadlej, Elzbieta Nowara, Cathy Eng, Eric Van Cutsem
PDF file - 76K, Supplemental Fig. S1. (A) Randomized phase Ib/II trial of panitumumab plus rilotumumab (AMG 102) or ganitumab (AMG 479). (B) CONSORT diagram for part 2. *Panitumumab 6 mg/kg; rilotumumab 10 mg/kg with dose de-escalation to 5 mg/kg as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87a99d014edea26951bac27336d2db7f
https://doi.org/10.1158/1078-0432.22447470.v1
https://doi.org/10.1158/1078-0432.22447470.v1
Autor:
Josep Tabernero, Dominic Smethurst, Elwyn Loh, Jennifer Gansert, Lisa Chen, Kelly S. Oliner, Ian McCaffery, Rui Tang, Hongjie Deng, Hans Prenen, Elena Elez, Joe Stephenson, Irina Davidenko, Edith Mitchell, Niall C. Tebbutt, Anna Świeboda-Sadlej, Elzbieta Nowara, Cathy Eng, Eric Van Cutsem
PDF file - 38K, Supplemental Fig. S5. The effect of baseline IGF and IGF-related protein expression on objective response rate.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::273b680cc3bdef871af4b840596e44f1
https://doi.org/10.1158/1078-0432.22447458
https://doi.org/10.1158/1078-0432.22447458
Autor:
Josep Tabernero, Dominic Smethurst, Elwyn Loh, Jennifer Gansert, Lisa Chen, Kelly S. Oliner, Ian McCaffery, Rui Tang, Hongjie Deng, Hans Prenen, Elena Elez, Joe Stephenson, Irina Davidenko, Edith Mitchell, Niall C. Tebbutt, Anna Świeboda-Sadlej, Elzbieta Nowara, Cathy Eng, Eric Van Cutsem
PDF file - 38K, Supplemental Fig. S2. Best percent change of the sum of longest diameters of target lesions from baseline to post-baseline. (A) Panitumumab plus rilotumumab.(B) Panitumumab plus ganitumab. (C) Panitumumab alone.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7baaa18fa476f138cb3e2f19e8234f5c
https://doi.org/10.1158/1078-0432.22447467
https://doi.org/10.1158/1078-0432.22447467
Autor:
Josep Tabernero, Dominic Smethurst, Elwyn Loh, Jennifer Gansert, Lisa Chen, Kelly S. Oliner, Ian McCaffery, Rui Tang, Hongjie Deng, Hans Prenen, Elena Elez, Joe Stephenson, Irina Davidenko, Edith Mitchell, Niall C. Tebbutt, Anna Świeboda-Sadlej, Elzbieta Nowara, Cathy Eng, Eric Van Cutsem
Purpose: Panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody (mAb), has demonstrated efficacy in patients with wild-type KRAS metastatic colorectal cancer (mCRC). Rilotumumab and ganitumab are investigational, fully h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7622ce0c79248463ad027204b93f26b2
https://doi.org/10.1158/1078-0432.c.6521079
https://doi.org/10.1158/1078-0432.c.6521079
Autor:
Josep Tabernero, Dominic Smethurst, Elwyn Loh, Jennifer Gansert, Lisa Chen, Kelly S. Oliner, Ian McCaffery, Rui Tang, Hongjie Deng, Hans Prenen, Elena Elez, Joe Stephenson, Irina Davidenko, Edith Mitchell, Niall C. Tebbutt, Anna Świeboda-Sadlej, Elzbieta Nowara, Cathy Eng, Eric Van Cutsem
PDF file - 86K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a03d34f89904dd718f5b4e4ebcb9eeb
https://doi.org/10.1158/1078-0432.22447455
https://doi.org/10.1158/1078-0432.22447455
Autor:
Jason A. Chesney, Antoni Ribas, Georgina V. Long, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew Haydon, John Hyngstrom, Johannes V. van Thienen, Sebastian Haferkamp, Josep Malvehy Guilera, Bernardo Leon Rapoport, Ari VanderWalde, Scott J. Diede, James R. Anderson, Sheryl Treichel, Edward L. Chan, Sumita Bhatta, Jennifer Gansert, Frank Stephen Hodi, Helen Gogas
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 41, iss 3
PURPOSE The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study. We report the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b46de78c04c83ea915b9c0fac797837
https://escholarship.org/uc/item/2967c9w2
https://escholarship.org/uc/item/2967c9w2
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8badceef0af92ffd8b3a736c40a1376
https://doi.org/10.1200/jco.2017.73.7379
https://doi.org/10.1200/jco.2017.73.7379
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Autor:
Jonathan Cebon, Igor Puzanov, Eugenio Fernandez, Scott J. Diede, Abraham Anderson, Thomas F. Gajewski, John M. Kirkwood, Robert H.I. Andtbacka, Reinhard Dummer, F. Stephen Hodi, Georgina V. Long, Ari M. Vanderwalde, Anthony J. Olszanski, Lisa Chen, Jennifer Gansert, Antoni Ribas, Michael E. Lassman, Kevin S. Gorski, Olivier Michielin, Josep Malvehy
Publikováno v:
Cell
Cell, vol 170, iss 6
Cell, vol 170, iss 6
Here we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on cytotoxic Tcell infiltration and therapeutic efficacy of the anti-PD-1 antibody pembrolizumab. Twenty-one patients with advanced mel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbb1ed2f3bd20491618b2cf045cd816b
https://europepmc.org/articles/PMC8034392/
https://europepmc.org/articles/PMC8034392/